Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Common Equity: 2022-2025

Historic Common Equity for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $13.4 million.

  • InMed Pharmaceuticals' Common Equity rose 38.06% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 38.06%. This contributed to the annual value of $13.4 million for FY2025, which is 45.93% up from last year.
  • InMed Pharmaceuticals' Common Equity amounted to $13.4 million in FY2025, which was up 45.93% from $9.2 million recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Common Equity registered a high of $13.4 million during FY2025, and its lowest value of $9.1 million during FY2022.
  • For the 3-year period, InMed Pharmaceuticals' Common Equity averaged around $11.6 million, with its median value being $12.1 million (2023).
  • Its Common Equity has fluctuated over the past 5 years, first decreased by 23.85% in 2024, then surged by 45.93% in 2025.
  • Over the past 4 years, InMed Pharmaceuticals' Common Equity (Yearly) stood at $9.1 million in 2022, then spiked by 33.17% to $12.1 million in 2023, then declined by 23.85% to $9.2 million in 2024, then surged by 45.93% to $13.4 million in 2025.